Prozac was introduced by Eli Lilly to the US market in January 1988. Zoloft and Paxil followed in 1991 and 1992, respectively. Some 45,000 reports of adverse reactions to Prozac have been filed with the FDA. These include reports of about 2500 deaths, with the large majority linked to suicide or violence.
READ MORE @ COUNTERPUNCH
skip to main |
skip to sidebar
Librarian by training, bipolar by genetics
Independent And Topical Information Updated Constantly
Librarian by training, bipolar by genetics.
Write to me at rsilberstein at gmail.com
Information on this site should not to be construed as medical or legal advice. Talk with your prescriber before making changes in your medications.
Write to me at rsilberstein at gmail.com
Information on this site should not to be construed as medical or legal advice. Talk with your prescriber before making changes in your medications.
Links
Archive of Past Posts
- ► 2009 (306)
- ► 2008 (340)
Blog Subjects
- . Combination Drug Therapy (1)
- .eli lilly (1)
- 'GAIN' (1)
- ” investigational drugs (1)
- "black box" warning (1)
- “expanded access programs (1)
- “fuzzy” diagnosis (1)
- “off-label” prescriptions (1)
- "u" EEG pattern (1)
- (MAOA) (1)
- 2010 uninsured predictions (1)
- Abilify (4)
- acid-sensing ion channel (ASIC) proteins (1)
- acquisition (1)
- acupuncture (1)
- acute adverse drug effects (3)
- acute coronary syndrome (1)
- acute coronary syndrome (ACS) (1)
- acute schizophrenia symptoms (2)
- acute treatment (2)
- ada (1)
- ADD (2)
- Adderall (1)
- addiction (2)
- addiction risks (1)
- addiction therapy (1)
- ADHD (25)
- ADHD medications (1)
- ADHD medications abuse (1)
- Adjunctive aripiprazole (1)
- Adjunctive psychotherapy (2)
- adjunctive therapy (1)
- adjunctive treatment (3)
- admission (1)
- adolescents (36)
- adoption (1)
- adult obesity (1)
- adult risk (1)
- adultdhood (1)
- adulthood (1)
- adulthood trauma (1)
- adults (5)
- Adverse drug effects (49)
- Adverse drug reactions (10)
- adverse effects (3)
- adverse side effects (4)
- advertising (4)
- Afghanistan (1)
- African Americans (2)
- African-Americans (1)
- age (2)
- Aging (1)
- Agomelatin (1)
- agomelatine (1)
- agression (2)
- aids (2)
- akathisia (1)
- Alaska (1)
- alcohol (2)
- allele (1)
- alternative mechanism (1)
- alternative medicine (2)
- alternative treatments (2)
- Alzheimer's (9)
- Alzheimer’s (2)
- Alzheimer’s Disease (1)
- Alzheimer's disease (AD) (2)
- Alzheimer’s Patients (2)
- American college of physicians(ACP) (1)
- American Psychiatric Association (3)
- American Psychological Association (1)
- American Recovery and Reinvestment Act (ARRA) (1)
- amitriptyline (1)
- amphetamines (1)
- AMPK (1)
- amygdala (3)
- angina (1)
- angiotensin receptor blockers (ARBs) (1)
- Angiotensin-converting enzyme (ACE) inhibitors (1)
- animal studies (1)
- Anorexia (1)
- anorexia nervosa (1)
- antdepressant use (1)
- anti-psychotics (1)
- Anticholinergics (2)
- anticonvulsant (6)
- anticonvulsants (5)
- antidepressant (10)
- antidepressant treatment (12)
- antidepressant adverse effects (1)
- antidepressant classes (1)
- antidepressant efficacy (2)
- Antidepressant Guideline (1)
- antidepressant prescribing (2)
- antidepressant sales (1)
- antidepressant side effects (1)
- antidepressant therapy (1)
- Antidepressant treatment (3)
- antidepressant use (6)
- antidepressants (120)
- antidepressants effectiveness (1)
- antidepressants effects (1)
- antiepileptics (1)
- antihypertensives (1)
- antipsychotic (3)
- antipsychotic medications (1)
- antipsychotic polypharmacy (1)
- antipsychotic therapy (1)
- antipsychotic treatment (4)
- antipsychotics (54)
- antipsychotics misuse (1)
- antipsychotics treatment (1)
- Antipsychotics use (2)
- anxiety (10)
- anxiety disorder (3)
- Anxiety disorders (5)
- approval policy (1)
- approval review (1)
- aripiprazole (3)
- armed forces (1)
- asian patients (3)
- assessment (1)
- Astra Zeneca Pharmaceuticals (1)
- AstraZeneca (5)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Atypical antipsychotics (41)
- atypical depressants (1)
- autism (4)
- autism spectrum disorders (1)
- autism spectrum disorders (ASD) (2)
- babies (1)
- back pain (2)
- bailout bill (1)
- behavioral pain management therapy (1)
- benefits (1)
- Bextra (1)
- bifeprunox (1)
- bioequivalency (1)
- biological psychiatry (1)
- biologics (3)
- biomarkers (3)
- biomedical device companies (1)
- biomedicine (1)
- biotech industry (1)
- biotechnology drugs (1)
- bipolar depression (18)
- bipolar disorder (44)
- bipolar disorder (BPD) (3)
- bipolar drug treament (1)
- bipolar I disorder (1)
- birth defects (5)
- Birth-Defects (1)
- black box warnings (1)
- black-box warnings (2)
- blood pressure (1)
- blood sugar and cholesterol monitoring (1)
- bone mineral density (BMD) (1)
- borderline personality disorder (2)
- boys (1)
- brain (7)
- brain cells (3)
- brain development (1)
- brain function (1)
- Brain Injury (1)
- brain neurobiology (2)
- brain pacemakers (1)
- brain research (2)
- brain scans (3)
- brain shrinkage (1)
- brain stimulation techniques (1)
- brain structures map (1)
- brain triggers (1)
- brain-stimulating devices (1)
- brain-stimulating drugs (1)
- brains (1)
- brand name (1)
- brand name drugs (1)
- breast cancer recurrence (2)
- breast feeding (1)
- Bristol-Myers Squibb (2)
- Britain (1)
- British physician (1)
- california (1)
- canada (2)
- cancer (5)
- cancer recurrence (2)
- cancer resistence (1)
- Carbamazepine (2)
- cardiac episode (1)
- cardiac risk (1)
- Cardiometabolic Ris (1)
- cardiovascular disease (2)
- cardiovascular disease risk (1)
- cardiovascular risk (2)
- Cardiovascular risk factors (1)
- cardiovascular side effects (1)
- careers (1)
- CATIE (1)
- causes (1)
- Celexa (3)
- Central Nervous System (CNS) disorders (1)
- cerebral inflammation (1)
- chemotherapy (1)
- childhood adversity (1)
- childhood intelligence (1)
- Childhood-onset schizophrenia (2)
- children (56)
- chorea (1)
- CHRONIC DEPRESSION (2)
- chronic diseases (2)
- chronic illness (1)
- chronic obstructive pulmonary disease (COPD) (1)
- Citalopram (3)
- Citalopram (Celexa) (2)
- civil rights (1)
- civil suit (2)
- class action lawsuit (2)
- clinical studies (1)
- clinical trials (7)
- clorgyline (1)
- Clozapine (6)
- cocaine (1)
- cocaine addiction (1)
- cognition (6)
- cognitive behavior therapy (CBT) (1)
- cognitive behavioral therapy (7)
- cognitive behaviour therapy (CBT) (2)
- cognitive behavioural therapies (1)
- cognitive behavioural therapy (1)
- cognitive behavioural therapy (CBT) (4)
- cognitive dysfunction (1)
- cognitive function (3)
- Cognitive Impairments (1)
- cognitive performance (1)
- cognitive symptoms (2)
- cognitive-behavioral therapy (1)
- Cognitive-Behavioral Therapy (cbt) (1)
- comorbidities (6)
- comorbidity (5)
- Compassion and Choices (1)
- compliance (3)
- compulsory treatment (1)
- computerized system (1)
- Concerta (3)
- concussions (1)
- congress (7)
- consumer medication information (1)
- consumer protection (1)
- consumers (2)
- contamination (1)
- continuing medical education (CME) seminars (1)
- Conventional antipsychotics (1)
- copayments (3)
- copd (1)
- coronary artery disease (CAD (1)
- coronary heart disease (2)
- Corporate Integrity Agreement (1)
- cortisol (1)
- cost effectiveness (1)
- counseling (1)
- counterfeits (1)
- coverage (1)
- CT (1)
- Cymbalta (3)
- cytochrome (CY) P450 system. Comorbidities (1)
- dea (1)
- death rate (4)
- death with dignity (1)
- Deep brain stimulation (DBS) (1)
- deep-brain stimulation (DBS) (1)
- delerium (1)
- delirium (1)
- delivery system (1)
- dementia (23)
- Dementia effects (1)
- Dementia Risk (2)
- dementia strategy (1)
- demographics (1)
- Depakote (1)
- department of justice (1)
- depot antipsychotics (1)
- depression (134)
- depression and bipolar disorder (1)
- Depression Test (1)
- Depression Treatment (12)
- Depression Treatment effectiveness (1)
- depression. pregnancy (3)
- developing world (1)
- diabetes (4)
- diagnosis (22)
- Diagnostic Guidelines (2)
- diagnostic technique (1)
- diagonosis (1)
- diet (1)
- differences (1)
- direct to consumer advertising (1)
- direct-to-consumer advertising (2)
- direct-to-consumer prescription drug advertising (1)
- disabilities (1)
- disability determination process (1)
- discontinuance (1)
- discrimination (3)
- disease (1)
- disposal methods (2)
- dissociative disorder (1)
- dna (2)
- doctor-assisted suicide (2)
- doctor-patient relationship (1)
- doctors (5)
- Dopamine (3)
- dosage (1)
- dr Joseph Biederman (1)
- Dr. Frank J. Ayd Jr. (1)
- Dr. Frank M. Berger (1)
- Dr. Joseph Biederman (3)
- Dr. Michael Reinstein (1)
- dr. Stephen V. Faraone (1)
- Dr. Timothy E. Wilens (1)
- drinking water (2)
- driving (1)
- drug treatment (8)
- drug advertisements (1)
- drug companies (39)
- drug company liability (1)
- drug costs (1)
- drug effectiveness (5)
- drug effects (1)
- drug industry (3)
- drug interactions (1)
- drug management (1)
- drug market (1)
- drug policy (1)
- drug prices (3)
- drug research (6)
- drug samples (1)
- drug studies (2)
- drug targeting (1)
- drug therapies (1)
- drug therapy (1)
- drug treament (1)
- drug treatment (7)
- drug trials (1)
- drug use (1)
- drug-drug interactions (DDIs) (1)
- drugmakers (1)
- drugs (1)
- drugs and medical devices (1)
- DSM-V (1)
- DSM's revision (1)
- dual diagnosis (1)
- duloxetine (1)
- dysphoria (1)
- early adulthood (1)
- early diagnosis (1)
- early onset (1)
- economic crisis (1)
- economic deprivation (1)
- ECONOMIC RECESSION (1)
- economy (3)
- education (1)
- eeoc (1)
- Efexor* XL (1)
- effectiveness (4)
- Effexor (2)
- Effexor XR (1)
- efficacy (3)
- efficacy. (1)
- elderlry (9)
- elderly (32)
- electric shock therapy (1)
- electrical stimulation (1)
- electroconvulsive therapy (ECT) (4)
- electroconvulsive therapy(ECT) (1)
- Electronic Health Records (EHR) (1)
- electrovestibulography (1)
- eledrly (1)
- Eli Lilly (20)
- emergency room visits (1)
- emergency rooms (3)
- emotional problems (1)
- employers (1)
- employment (1)
- epigenetics (2)
- epilepsy (4)
- Epileptics (1)
- escitalopram (2)
- Estrogen (1)
- ethics (1)
- ethnic minorities (1)
- ethnicity (3)
- etiology (6)
- EU (2)
- European Commission (2)
- evidence based medicine (1)
- evidence-based treatment (1)
- exercise (5)
- experimental medicines (1)
- facial emotion (1)
- falls (3)
- family history (1)
- family support (1)
- Fanapt(TM) (iloperidone) (2)
- Father's Age (1)
- FDA (55)
- FDA advisers (1)
- FDA advisory committee (2)
- FDA advisory panel (1)
- fda approval (6)
- fda approval process (1)
- federal courts (1)
- Federal Trade Secrets Act (1)
- felony fraud (1)
- fertility (1)
- fetal brain defects (1)
- fibromyalgia (2)
- fibromyalgia syndrome (FMS) (1)
- finances (2)
- financial ties (1)
- first generation antipsychotics(FGA) (2)
- first-generation antipsychotics (FGA) (3)
- florida (1)
- fluoxetine (3)
- fluoxetine HCl (1)
- fmri (2)
- follow-up studies (1)
- forensics (1)
- Forest Laboratories (1)
- foster care (2)
- fta (1)
- ftactures (1)
- functional magnetic resonance imaging (fMRI) (1)
- functional MRI (fMRI (1)
- funding (3)
- gabapentin (2)
- gamma-aminobutyric acid (GABA) (1)
- gao (1)
- gao review (1)
- Gastrointestinal Bleeding (1)
- gender (1)
- gender difference (1)
- general practitioners (1)
- generalized anxiety disorder (1)
- generic (1)
- generic biologics (1)
- generic biologics (biogenerics) (1)
- generic competition (1)
- generic drug industry (1)
- Generic drugs (1)
- Generic drugs prices (1)
- generic medications (1)
- generic risperidone (1)
- generics (8)
- genes (13)
- genetic damage (1)
- genetic risk (2)
- genetic testing (1)
- genetic variation (1)
- genetic variations (1)
- genetics (20)
- genetics of psychiatric illnesses (1)
- genetics research (1)
- Geodon (3)
- gepirone ER (1)
- Ghost authors (1)
- Ghost writing (1)
- ghrelin (1)
- GlaxoSmithKline (6)
- GlaxoSmithKline (GSK) (1)
- global trends (1)
- glucose (1)
- glutamate (3)
- good health habits (1)
- google search ads (1)
- government antipsychotic review (1)
- grants (1)
- Grassley (1)
- Great Britain (1)
- grey matter (1)
- hallucinations (1)
- haloperidol (3)
- Harvard researchers (1)
- hdl (1)
- head and neck cancer (1)
- headache (1)
- health care costs (1)
- health fraud (1)
- Health insurance companies (3)
- health inurance coverage (1)
- health policy (1)
- health-care insurance overhaul (1)
- healthcare lobbyists (1)
- healthcare reform legislation (1)
- heart disease (5)
- heart failure (3)
- heart failure treatment (1)
- heart patients (1)
- heart problems (1)
- height (1)
- heredity (1)
- heroin addiction (1)
- hippocampal neurogenesis (1)
- hippocampus (2)
- HIV (3)
- homeless (1)
- homeostasis (1)
- hopelessness (1)
- hormonal transitions (1)
- hospital treatment (1)
- hospitalization (2)
- hospitalization patterns (1)
- housing (1)
- human rights (1)
- Huntington's disease (1)
- hyperglycemia (1)
- hypertension (1)
- hypoxia (1)
- illegal marketing (2)
- illegal promotion (1)
- illness (2)
- iloperidone (3)
- imaging techniques (1)
- immune system mutations (1)
- immunity (1)
- immunity law (1)
- implementation (1)
- impulsivity (1)
- incidence (4)
- industry-financed activities (1)
- infant mortality (1)
- infants (1)
- infectious disorders (1)
- inflammatory markers in blood (1)
- information access (1)
- Injectable Risperidone (1)
- insomnia (3)
- insurers (1)
- integrated treatment strategies (1)
- intellectual disability (1)
- internet addiction (1)
- Internet marketing (1)
- internet pharmacies (3)
- Internet-based therapy (1)
- interrogations (1)
- Invega (4)
- INVEGA™ (1)
- ipsychotic (1)
- irritability (1)
- Irritable Bowel Syndrome (2)
- job loss (1)
- Johnson AND Johnson (1)
- Johnson n Johnson (3)
- Journal articles (1)
- judicial documents (1)
- ketamine (3)
- khat (1)
- kickbacks (1)
- kidney disease (1)
- kidney transplantation (1)
- labeling (1)
- labelling (1)
- labels (1)
- Lamictal (1)
- lamotrigine (1)
- Las Vegas Valley (1)
- Latinos (1)
- legality (1)
- legislation (4)
- Lexapro (5)
- Lexapro (escitalopram) (1)
- licensing (1)
- lifespan (2)
- lifestyle (1)
- lifestyle changes (1)
- lipids (1)
- Lipitor (1)
- lithium (4)
- litigation (6)
- lobbying (1)
- London (1)
- loneliness (1)
- long-acting injection (LAI) (1)
- long-actingectable antipsychotic therapy (LAT inj) (1)
- long-term outlook (1)
- longevity (1)
- low risk patients (1)
- lurasidone (2)
- Lyrica (1)
- lzheimer's (1)
- magnetic resonance imaging (MRI) (1)
- major depression (2)
- major depression risk (1)
- major depressive disorder (1)
- major depressive disorder (MDD) (4)
- male fertility (1)
- management (1)
- Management strategies (1)
- mania (1)
- manic episodes (1)
- MAO inhibitors (1)
- marketing (6)
- marketing SETTLEMENTS (1)
- marketing tactics (1)
- meaningful use (1)
- medicaid (5)
- Medicaid patients (1)
- medical comorbidities (2)
- medical conflicts of interest (1)
- medical device companies (1)
- medical ethics (1)
- medical Ghostwriting (1)
- Medical Illnesses (1)
- medical insurance (1)
- medical journal articles (1)
- medical journals (2)
- medical research (1)
- medical researcher (1)
- Medical School (1)
- medical students (1)
- medicare (2)
- Medicare Part D (1)
- medication (9)
- medication errors (3)
- medication history (1)
- medication use (5)
- medications (1)
- medicines (1)
- melatonin (1)
- memory (3)
- memory loss (3)
- men (1)
- menopause (1)
- mental challenges (1)
- mental disorder (2)
- Mental Disorders (2)
- mental health (10)
- mental health paritry (3)
- mental health problems (1)
- mental health professionals shortage (1)
- mental health services (3)
- Mental Health Stereotypes (1)
- mental illness (33)
- Mental Stress Training (1)
- mentally ill (2)
- Metabolic Abnormalities (1)
- metabolic disorders (1)
- metabolic monitoring (1)
- Metabolic screening (2)
- metabolic side effects (5)
- metabolic syndrome (1)
- metabolic testing (1)
- metabolism (2)
- Metformin (2)
- methamphetamine addiction (1)
- MHAT IV (1)
- mianserin (1)
- Michigan (1)
- midlife (1)
- mild depression (2)
- military (2)
- Military Mental Health System (1)
- military personnel (1)
- Miltown (1)
- Mindfulness Based Cognitive Therapy (MBCT (1)
- mixed episodes (1)
- molecular basis (1)
- Monoamine oxidase-A (1)
- monoaminergic antidepressants (1)
- mood and psychotic disorders (1)
- mood disorders (3)
- mood stabilizers (1)
- mood-stabilizers (1)
- moods (1)
- morphine (1)
- mortality (5)
- MRI (2)
- multiple prescriptions (2)
- multiple sclerosis (1)
- NAMI (1)
- nanoparticles (1)
- National Academy of Sciences (NAS) (1)
- National Coalition of Mental Health Consumer/Survivor Organizations (NCMHCSO) (1)
- natural selection (1)
- negative studies (1)
- negative symptoms (5)
- neuregulin (1)
- neurogenesis (3)
- Neuroimaging (1)
- neuroleptics (2)
- Neurontin (3)
- neuropathic pain (1)
- Neuropathy (1)
- neurotransmitters (4)
- New Orleans (1)
- newborn complications (1)
- NIDA (1)
- NIH (4)
- NIMH (4)
- non-English speakers (1)
- non-Hodgkin lymphoma (NHL) (1)
- nonadherence (2)
- noncompliance (1)
- nonconventional therapies (1)
- Nonconventional Treatment (1)
- nondrug therapy (1)
- nonelderly Americans (1)
- noradrenaline (1)
- Norah Vincent (1)
- norepinephrine (3)
- nortriptyline (3)
- nortriptyline (Aventyl (1)
- Novartis (2)
- nursing homes (3)
- nursing-homes (1)
- nurture (1)
- Obama administration (1)
- Obama budget (1)
- obesity (4)
- obsessive compulsive disorder (OCD) (1)
- obsessive compulsive disorders (OCD) (1)
- obsessive-compulsive disorder (OCD) (2)
- obstetrics (1)
- ocd (4)
- Off-Label Drug Use (13)
- Off-Label Drug Use. eli lilly (1)
- Off-Label Drug Use. zyprexa (3)
- off-Label Prescribing (5)
- off-label use (4)
- off-label uses (1)
- Office of National Drug Control Policy (1)
- Ohio (1)
- OHSU (1)
- Olanzapine (7)
- olanzapine(Zyprexa) (1)
- old age (1)
- omega-3 fatty acids (1)
- omega-3 polyunsaturated fatty acid (1)
- once-monthly injectible (1)
- online prescriptions management (1)
- online sales. medications (1)
- opamine antagonists (1)
- opiods (1)
- opioid receptors (1)
- Oregon (1)
- organic markers (1)
- osteoporosis (3)
- outpatients (1)
- overdose deaths (1)
- overmedication (1)
- pain (2)
- pain management (2)
- pain-predominant gastrointestinal disorders (1)
- painkillers (1)
- paliperidone (1)
- paliperidone ER (1)
- paliperidone palmitate (1)
- palliative care (1)
- Pamelor) (1)
- parental depression (1)
- parents training (1)
- parity (1)
- Parkinson's (2)
- Parkinson's disease (1)
- Parkinson's disease (PD) (1)
- paroxetine (2)
- Paroxetine(Paxil) (1)
- patents (3)
- pathophysiology (1)
- patients’ subjective experience (1)
- PatientsLikeMe (1)
- Paxil (7)
- payments (3)
- pediatric and adolescent patients (1)
- Pediatric Bipolar Disorder (2)
- pediatric patients (1)
- Pediatricians (1)
- peer review (1)
- perceived disability (1)
- performance (1)
- perinatal period (1)
- perphenazine (1)
- persistent pulmonary hypertension (PPHN) (1)
- personal shame (1)
- PET (1)
- PET Scans (1)
- Pexeva (1)
- Pfizer (7)
- pharmaceutical companies (1)
- pharmaceutical industry (4)
- pharmaceutical representatives (1)
- pharmaceuticals (1)
- pharmacies (1)
- pharmacists collaboration (1)
- Pharmacogenetics (1)
- Pharmacotherapy (2)
- phenytoin (1)
- physical comorbidities (1)
- physical exercise (1)
- physical health services access (1)
- physical impairments (1)
- physical inactivity (1)
- physician education (1)
- physician ethics (1)
- physicians (3)
- pimozide (1)
- placebos (3)
- pneumonia (3)
- politicians (1)
- Positive symptoms (2)
- Post-Seizure Depression (1)
- post-traumatic stress disorder (PTSD) (1)
- postoperative cognitive decline (POCD) (1)
- postpartum depression (1)
- posttraumatic stress disorder (PTSD) (1)
- predictors (1)
- preemption (2)
- preemptive treatment (1)
- pregnancy (13)
- pregnenolone (1)
- premature births (2)
- PREMATURE DEATH (4)
- Premature delivery (1)
- Premenstrual Syndrome (1)
- preschoolers (1)
- Prescribing (3)
- prescription combinations (1)
- prescription costs (5)
- prescription data mining (1)
- prescription drugs (13)
- prescription drugs costs (1)
- Prescription errors (1)
- prescription rate (2)
- prescriptions (7)
- presenting symptoms (1)
- President Obama (1)
- presidential campaign (1)
- preterm birth (2)
- preventable injuries (1)
- prevention (2)
- prevention and treatment (1)
- primary care physicians (PCP) (1)
- Pristiq (1)
- private psychiatric care (1)
- Proctor and Gamble (1)
- professional discipline (1)
- professional medical writers (1)
- promotional payments (1)
- Prostaglandins (1)
- Prozac (10)
- pseudopatieny history (1)
- Psychedelic drugs (1)
- psychiatric crisis (1)
- psychiatric diagnosis (1)
- Psychiatric Disability (1)
- psychiatric disorders (12)
- Psychiatric Drugs (4)
- Psychiatric Emergencies (1)
- Psychiatric epidemiology (2)
- psychiatric genetics literature (1)
- Psychiatric Illness (1)
- psychiatric medications (4)
- psychiatric outcomes (1)
- psychiatric patients (1)
- psychiatric side effects (1)
- Psychiatric Solutions Inc (1)
- Psychiatric Symptoms (4)
- psychiatric system (1)
- psychiatric treatment (1)
- psychiatric ward (1)
- psychiatrists (12)
- psychiatry (3)
- psychoanalysis (1)
- psychological effects (2)
- psychological symptoms (1)
- psychopathology (1)
- psychosocial/behavioral therapy (1)
- psychosomatics (1)
- psychostimulants (1)
- psychosurgery (1)
- psychotherapy (6)
- Psychotropic Drugs (4)
- psychotropic medications (9)
- psychotropics (1)
- PTSD (10)
- purchase strategies (1)
- purchasing strategy (1)
- quality of life (1)
- quetiapine XR (1)
- R and D (1)
- racial minorities (1)
- rapid-cycling bipolar disorder (1)
- reboxetine (1)
- recent-onset schizophrenia (1)
- recession (1)
- recovery (1)
- recurrence (1)
- reform (1)
- relapse (1)
- relapse rate (1)
- remission (1)
- repackaging (1)
- reparative therapy (1)
- Repetitive Behaviors (1)
- research (2)
- research and development (1)
- Research and Development (1)
- research ghostwriting (1)
- research paradigms (1)
- Respen-A (1)
- retailers (1)
- review (1)
- rheumatoid arthritis (RA) (1)
- right cerebral hemisphere (1)
- rimonabant (1)
- risk (2)
- risk factor (4)
- risk information (1)
- risk of dying (1)
- risk of falling (1)
- Risperdal (11)
- RISPERDAL CONSTA (1)
- risperidone (5)
- risperidone (Risperdal) (2)
- Risperidone long-acting injectable (RLAI) (1)
- risperidone long-acting injection (RLAI) (1)
- Ritalin (6)
- routine screening (1)
- Sabril (1)
- safety (1)
- safety warnings (1)
- sales tactics (1)
- SAMHSA (1)
- Saphris (1)
- Saphris (asenapine) (1)
- schedules (1)
- Schering-Plough (2)
- schizophrenia (3)
- school intervention programs (1)
- Schwarzenegger (1)
- searchable database (1)
- seasonal affective disorder (1)
- Seasonal Affective Disorder (SAD) (4)
- Second-generation antipsychotic drugs (1)
- second-generation antipsychotics (3)
- second-generation antipsychotics (SGA) (1)
- selective serotonin and norepinephrine reuptake inhibitor (SNRI) (1)
- self-esteem (1)
- seniors (2)
- Seroquel (9)
- Seroquel adverse drug effects (1)
- SEROQUEL XR (1)
- SEROQUEL XR(R) (1)
- SEROQUEL(R) (1)
- serotonin (18)
- serotonin receptors (2)
- serotonin syndrome (1)
- serotonin system (1)
- Seroxat (1)
- sertindole (2)
- Sertraline (1)
- sertraline (Zoloft) (1)
- severe depression (1)
- severity (1)
- sexual dysfunction (2)
- sexual oreintation (1)
- sexual side effects (1)
- siblings (1)
- side effects (2)
- sildenafil (1)
- sleep deprivation (1)
- sleep disorders (2)
- sleepiness (1)
- smoking (1)
- snris (2)
- spinal cord injuries (1)
- SRI (1)
- SSRIs (56)
- ssris. snris (1)
- St. John's wort (1)
- state litigation (1)
- statins (1)
- Stevens-Johnson Syndrome (1)
- stigma (14)
- Stimulant medication (1)
- stimulant medications (1)
- Stimulating immune function (1)
- Strattera (1)
- stress (9)
- stress hormones (1)
- stress-related psychiatric disorders (1)
- strokes (2)
- study (1)
- Suboxone (1)
- subpoena (1)
- substance abuse (2)
- substance use disorders (1)
- Sudden Cardiac Death (2)
- sudden cardiac death (SCD) (1)
- Sudden Cardiac Deaths (1)
- sudden death (1)
- suicidal ideation (1)
- suicidal risk (1)
- suicidal thinking (1)
- suicide (29)
- suicide prevention (2)
- suicide rate (1)
- suicide risk (3)
- suicide warnings (2)
- suicides (5)
- Suprane (1)
- supreme court (2)
- surgery (3)
- survey (1)
- sychiatric medications (1)
- Symbyax (1)
- symptoms (3)
- synptoms (1)
- Tamoxifen (2)
- Teen suicides (1)
- teenagers (6)
- teens (1)
- terminal illness (1)
- tetrabenazine (1)
- thalamus (1)
- theory (1)
- therapy (8)
- Thorazine (3)
- topiramate (1)
- toxic epidermal necrolysis (1)
- tranquilizers (1)
- Transcranial magnetic stimulation (2)
- Transcranial magnetic stimulation (TMS) (1)
- transcranial magnetic stimulation(TMS) (1)
- transdermal patch (1)
- transparency (1)
- traumatic brain injury (2)
- trazodone (1)
- treatment (64)
- treatment efficacy (1)
- treatment guidelines (1)
- treatment protocols (1)
- treatment resistance (1)
- treatment response (1)
- treatment strategy (1)
- treatment-resistant bipolar affective disorder (1)
- Treatment-Resistant Depression (1)
- Treatment-Resistant Depression (TRD) (2)
- Treatment-Resistant Depression in Adolescents (TORDIA) (1)
- treatment-resistant schizophrenia (1)
- tricyclic antidepressants (7)
- Tricyclic antidepressants (TCAs) (3)
- triggering enzyme (1)
- Trilafon (1)
- type 2 diabetes (2)
- typical antipsychotics (2)
- u.s courts (1)
- U.S prescription usage (1)
- U.S. (4)
- U.S. military (1)
- U.S. Public Mental Health System (1)
- U.S. Senate (1)
- u.s. troops (1)
- U.S.army (1)
- UK (4)
- UK Alzheimer’s (1)
- unapproved prescription drugs (1)
- undercover patients (1)
- underreported (1)
- unemployment (1)
- united kingdom (2)
- United States (1)
- US (1)
- US Army (1)
- US Department of Justice (1)
- us military (1)
- US Troops (2)
- Valdoxan (1)
- valproate (2)
- Vanda Pharmaceuticals (4)
- Vascular dementia (1)
- vascular depression (1)
- vascular disease (1)
- venlafaxine (1)
- veterans (9)
- veterans. treatment (1)
- veteransjavascript:void(0) (1)
- Vets Prevail (1)
- Vfend (1)
- Viagra (2)
- violence (3)
- Vitamin D Levels (1)
- Vyvanse (1)
- warning labels (1)
- warning signs (1)
- warnings (1)
- Washington (1)
- Web-based counseling (1)
- website (1)
- weight (3)
- weight gain (2)
- Wellbutrin (1)
- Wellbutrin XL (1)
- wholesale drug price increases (1)
- withdrawal symptoms (1)
- withdrawl side effects (1)
- women (9)
- Wyeth (5)
- young adults (2)
- younger children (1)
- youth (3)
- Ziprasidone (1)
- ziprasidone (Geodon) (1)
- Zoloft (6)
- Zyprexa (19)
Roy
Librarian by training, bipolar by genetics